OBJECTIVES : To compare the cost-effectiveness of prescribing biologics (secukinumab, golimumab, certolizumab pegol, ustekinumab, adalimumab, etanercept, and infliximab including biosimilars) for adult bio naïve patients with active psoriatic arthritis in Russia.

METHODS : Based on data on the efficacy of compared treatment regimens, data on the cost of drugs and medical services, as well as the frequency of their provision the cost-effectiveness analysis was carried out. According to national requirements for performance of cost-effectiveness results, we demonstrated difference (%) in the cost-effectiveness ratio between analysed treatment options. The study had a time horizon of 3 years. The discount rate was 3% per year. The evaluation of therapy effectiveness was based on ACR 20/50/70 response criteria.

RESULTS : Cost-effectiveness ratio of secukinumab is on average 65% and 55% lower than the cost-effectiveness ratio of treatment with certolizumab pegol, golimumab, ustekinumab, adalimumab, etanercept and infliximab in the first and subsequent years of therapy, in accordance.

CONCLUSIONS : Estimation of costs and efficacy showed that treatment with secukinumab is characterised by lower costs per unit of efficacy (ACR 20/50/70 response), relative to the indicators of the compared drugs in the first and subsequent years of therapy adult bio naïve patients with active psoriatic arthritis.